Sugi Predict

Sugi Predict / Compounds / SCHEMBL374209

SCHEMBL374209

SCHEMBL374209

Cc1cccc(C)c1N=C=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 2/20 0.56
▸ GABRB2 P47870 2/20 0.56
▸ CYP3A4 P08684 4/20 0.54
▸ TRPA1 O75762 3/20 0.42
▸ ATM Q13315 3/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ CYP2A6 P11509 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ TSHR P16473 2/20 0.36
▸ ACHE P22303 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ GRIN2D O15399 2/20 0.35
▸ GRIN3B O60391 2/20 0.35
▸ GRIN1 Q05586 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28201284 0.93 GABRA1 (0.50) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL1133364 0.89 GABRA1 (0.50) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL30520271 0.87 CYP3A4 (0.63) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL20145 0.87 CYP3A4 (0.63) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL30390691 0.85 GABRA1 (0.52) GABRA1GABRB2CYP3A4TRPA1ATM
Methane SCHEMBL10941733 0.85 CYP3A4 (0.61) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL10614896 0.85 GABRA1 (0.47) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL6901482 0.85 GABRA1 (0.47) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL8370425 0.85 GABRA1 (0.47) GABRA1GABRB2CYP3A4TRPA1ATM
SCHEMBL160980 0.85 GABRA1 (0.52) GABRA1GABRB2CYP3A4TRPA1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1059 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509547-B2 Synthesis of linear polyoxazolidinones using uretdiones as diisocyanate component BASF SE (DE) 2025-12-30 — — US claimed
US-20250051268-A1 METHOD FOR PREPARING ISOCYANATE BY MEANS OF GAS-PHASE SOLVENT-FREE METHOD MOJIA (SHANGHAI) BIOTECH CO., LTD. (CN) 2025-02-13 — — US claimed
CN-118772206-A Isocyanorhodium (I) zwitterionic complex, preparation method thereof, micelle, nano diagnosis and treatment probe and anticancer drug 兰州大学 2024-10-15 — — CN claimed
CN-118084961-A Rare earth metal amino compound and preparation method and application thereof 安徽师范大学 2024-05-28 — — CN claimed
WO-2024007204-A1 METHOD FOR PREPARING ISOCYANATE BY COMBINING SUPERCRITICAL PHOSGENATION METHOD WITH PIPING METHOD 摩珈(上海)生物科技有限公司 2024-01-11 — — WO claimed
US-20230348657-A1 SYNTHESIS OF LINEAR POLYOXAZOLIDINONES USING URETDIONES AS DIISOCYANATE COMPONENT BASF SE (DE) 2023-11-02 — — US claimed
CN-116769094-A Binuclear vanadium catalyst containing binghAC ligand, and preparation method and application thereof 合肥工业大学 2023-09-19 — — CN claimed
CN-113105364-B Method and system for producing isocyanates 广安摩珈生物科技有限公司 2023-08-08 — — CN claimed
CN-111566518-B Polythiourethane plastic lens SKC株式会社 2023-07-28 — — CN claimed
CN-111471171-B Arylsulfonic acid intermediate, preparation method thereof and application of aryl sulfonic acid intermediate in synthesizing low-temperature-sensitivity additive for concrete 江苏苏博特新材料股份有限公司 2023-07-18 — — CN claimed
US-20040215002-A1 Colorant compositions XEROX CORPORATION 2004-10-28 — — US claimed
US-20040215038-A1 Colorant precursor compositions XEROX CORPORATION 2004-10-28 — — US claimed
US-20040215022-A1 Colorant compositions XEROX CORPORATION 2004-10-28 — — US claimed
US-6790267-B1 METHINE COLORANT COMPOUNDS FOR PHASE CHANGE INKS XEROX CORPORATION 2004-09-14 — — US claimed
US-20040167249-A1 Phase change inks with isocyanate-derived antioxidants and UV stabilizers XEROX CORPORATION 2004-08-26 — — US claimed
US-6764541-B1 Colorant compositions XEROX CORPORATION 2004-07-20 — — US claimed
US-6652635-B2 Cyan phase change inks XEROX CORPORATION 2003-11-25 — — US claimed
US-20030079645-A1 Cyan phase change inks XEROX CORPORATION 2003-05-01 — — US claimed
EP-0325620-A1 METHOD FOR THE PREPARATION OF AMIDINO-UREA DERIVATIVES REANAL FINOMVEGYSZERGYAR (HU) 1989-08-02 — — EP claimed
WO-1988007990-A1 METHOD FOR THE PREPARATION OF AMIDINO-UREA DERIVATIVES REANAL FINOMVEGYSZERGYÁR (HU) 1988-10-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040215022-A1 Colorant compositions ARSA, TST, IK GABRA1 3037/4885GABRB2 3589/4885CYP3A4 974/4885
US-20250051268-A1 METHOD FOR PREPARING ISOCYANATE BY MEANS OF GAS-PHASE SOLVENT-FREE METHOD TST, GRHPR, IDH2 GABRA1 4469/4885GABRB2 4180/4885CYP3A4 802/4885
US-12509547-B2 Synthesis of linear polyoxazolidinones using uretdiones as diisocyanate component BMP1, BMP4, PBRM1 GABRA1 1107/4885GABRB2 537/4885CYP3A4 1801/4885
US-20040215038-A1 Colorant precursor compositions RB1, SULT1A1, CBR1 GABRA1 3481/4885GABRB2 4231/4885CYP3A4 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.